IP Library › Granted Patent US 11,596,678
Granted Patent B2
US 11,596,678 · App. 16/465,691 · Granted Mar 7, 2023

Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Inventors: David Weiner (Merion, PA); Ami Patel (Philadelphia, PA); Sarah Elliott (Pullman, WA)
Assignees: The Trustees of the University of Pennsylvania; The Wistar Institute of Anatomv and Biologv
A61K39/12A61P31/14A61P37/04C07K14/005A61K2039/53C12N2760/14222C12N2760/14234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,678
App. No.
16/465,691
Granted
Mar 7, 2023
Kind
B2
Abstract

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Claims (24)

1. An immunogenic composition comprising a nucleic acid molecule, wherein the nucleic acid molecule encodes a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

2. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is selected from the group consisting of a DNA molecule and an RNA molecule.

3. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

a) a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, and

b) an immunogenic fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.

4. The immunogenic composition of claim 1 , wherein a nucleotide sequence encoding the peptide is operably linked to at least one regulatory sequence selected from the group consisting of a start codon, an IgE leader sequence and a stop codon.

5. The immunogenic composition of claim 4 , wherein the nucleic acid molecule encodes a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6,

operably linked to an amino acid sequence as set forth in SEQ ID NO:8.

6. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises an expression vector.

7. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.

8. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

9. The immunogenic composition of claim 1 , further comprising an adjuvant.

10. A nucleic acid molecule encoding a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

11. The nucleic acid molecule of claim 10 , wherein the nucleic acid molecule is selected from the group consisting of a DNA molecule and an RNA molecule.

12. The nucleic acid molecule of claim 10 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

a) a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, and

b) an immunogenic fragment of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5.

13. The nucleic acid molecule of claim 10 , wherein the encoded peptide is operably linked to at least one regulatory sequence selected from the group consisting of a start codon, an IgE leader sequence and a stop codon.

14. The nucleic acid molecule of claim 13 , wherein the nucleic acid molecule encodes a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6,

operably linked to an amino acid sequence as set forth in SEQ ID NO:8.

15. A method of inducing an immune response against a Marburgvirus antigen in a subject in need thereof, the method comprising administering an immunogenic composition of claim 1 to the subject.

16. The method of claim 15 , wherein administering includes at least one of electroporation and injection.

17. A method of treating or preventing a Marburgvirus associated pathology in subject in need thereof, the method comprising administering an immunogenic composition of claim 1 to the subject.

18. The method of claim 17 , wherein the Marburgvirus associated pathology is at least one of Marburgvirus infection and hemorrhagic fever.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2023
From: WEINER, DAVID; PATEL, AMI; ELLIOTT, SARAH
To: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Reel/Frame 062406/0544 →
Continuity (2)
Provisional Application 62429473 · Dec 2, 2016
Related Publication 20190290751A1 · Sep 26, 2019
Cited By (1)
US 12,268,735